All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Global socioeconomic disparities in ALL: Diagnostic challenges
Marisa Felice (Argentina) and Shaun Fleming (Australia) discussed the socioeconomic disparities in the diagnosis of pediatric and adult patients with ALL.
Real-world efficacy of CAR T cells for posttransplant relapse in patients with B-ALL
In this article, we summarize the results of the first real-world study of tisa-cel in patients with B-ALL.
Dasatinib with intensive chemotherapy in newly diagnosed pediatric patients with Ph+ ALL
This article summarizes a publication by Hunger et al. on the efficacy of dasatinib with intensive chemotherapy in pediatric Philadelphia chromosome-positive ALL.